Angiotech in search of AAA stent-graft
This article was originally published in The Gray Sheet
Executive Summary
University of British Columbia will license to pharmaceutical firm its next-generation stent-endograft coating technology to treat abdominal aortic aneurysms, Angiotech notes March 17. Jointly developed, the drug coating promotes fibrous (scar) tissue growth and creates a biologic anchor for the stent. Angiotech has begun seeking device development partners...
You may also be interested in...
Angiotech Launches Orthopedics Strategy With Orthovita Pact, NeuColl Buy
Angiotech's marketing agreement with Orthovita for its CoStasis hemostatic spray, and NeuColl purchase, provide an initial orthopedics presence as the firm develops drug/device combinations for the sector
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
ImmunityBio Will Aim Anktiva At Large Share Of Bladder Cancer Market
Execs Richard Adcock and Patrick Soon-Shiong told Scrip the company sees an addressable US population of about 20,000 and is aiming for ease of physician adoption.